摘要
采用以羟磷灰石和α-磷酸三钙两晶相为基的无机骨水泥（HAC）作为药物缓释载体，载入5％去甲万古霉素（NVCM）药物后组成复合体，通过动物骨内植入，采用自身对照的方式与未载药HAC进行对比，在不同时期取材通过组织学和扫描电镜观察HAC载药与否植入材料对骨融合能力的影响。结果表明，载5％NVCM药物的HAC复合体仍具有良好的骨结合性、骨传导性和缓慢的生物降解性，药物的载入对HAC的骨融合能力未见明显影响．
To investigate the osteocompatibility of hydroxyapatite bone cement with 5% norvancomycin （HAC/NVCM composite）. The bilateral radial bone defects models in rabbits were first prepared with no drug loaded HAC and HAC/NVCM composite putting in each side. Then the animals were divided into three intervals in order to compare the osteocompatibility of each side using histological and SEM observation at 1, 3 and 6M respectively. The results indicated that the HAC was found to set without interfering by NVCM added and HAC/NVCM composite has good biological properties and good osteocompatibility. HAC/NVCM composite can effectively control the inflammation reaction and promote the wound healing. It can widely be used in the prophylaxis and treatment of bone infection and bone defect.
出处
《功能材料》
EI
CAS
CSCD
北大核心
2007年第A05期1702-1705,共4页
Journal of Functional Materials
基金
国家自然科学基金资助项目（30470480）：上海市重点学科（特色学科）建设资助项目（T0202）
上海市科委发展基金资助项目（0607H1294）
关键词
羟磷灰石骨水泥:去甲万古霉素:药物载体
缓释
骨融合
hydroxyapatite bone cement（HAC）
norvancomycin（NVCM）
drug carrier
slow-release
osteocompatibility
